methyl 4-<(6-amino-2,3-dihydrobenz-1,4-oxazin-4-yl)methyl>-3-methoxybenzoate | 107754-41-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-<(6-amino-2,3-dihydrobenz-1,4-oxazin-4-yl)methyl>-3-methoxybenzoate
• 英文别名: methyl 4-(6-amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)-3-methoxybenzoate；Methyl 4-(6-amino-2,3-dihydrobenz-1,4-oxazin4-ylmethyl)-3-methoxybenzoate；methyl 4-[(6-amino-2,3-dihydro-1,4-benzoxazin-4-yl)methyl]-3-methoxybenzoate
• CAS: 107754-41-6
• 化学式: C₁₈H₂₀N₂O₄
• 分子量: 328.368
• InChiKey: QZYRCKYKMJGJMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-<(6-amino-2,3-dihydrobenz-1,4-oxazin-4-yl)methyl>-3-methoxybenzoate 在 4-二甲氨基吡啶 、 lithium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 56.0h， 生成 4-<<6-(2-cyclopentylacetamido)-2,3-dihydrobenz-1,4-oxazin-4-yl>methyl>-3-methoxybenzoic acid
  参考文献：
  名称：

  Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides

  摘要：

  The dissociation constants (KB) at the LTD4 receptor on guinea pig trachea of a series of monocyclic and bicyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides have been measured. The KB was found to be remarkably tolerant of changes in the electronic constitution and lipophilicity of the bicyclic ring system (template). Thus, N-[4[[6-[[(cyclopentyloxy)carbonyl]amino]benzimidazol-1- yl]methyl]-3-methoxybenzoyl]benzenesulfonamide (11a) and N-[4-[[5-[[(cyclopentyloxy)carbonyl]amino]benzo[b]thien-3- yl]methyl]-3-methoxybenzoyl]benzene-sulfonamide (25a) had closely similar affinities (pKB, 9.20 and 9.31, respectively; LTE4 as agonist). It has been shown that the hetero-ring of the template need not be aromatic in order to achieve high affinity, since indoline 31 and 2,3-dihydrobenz-1,4-oxazines 37a-c had pKBs greater than 9. Further, it has been shown that an o-aminophenone (see 42 and Figure 3) can function as a template; the template in 42 [see iii] is bicyclic by virtue of the presence of an intramolecular hydrogen bond. In contrast, when the template is a phenyl ring (48), receptor affinity is markedly reduced. These findings support the notion that central bicyclic ring system in this family of peptidoleukotriene antagonists is a molecular feature which helps to preorganize the acylamino and acidic chains and thereby facilitate the molecular recognition event.

  DOI：

  10.1021/jm00171a043
• 作为产物：
  描述：

  4-溴甲基-3-甲氧基苯甲酸甲酯 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 sodium iodide 作用下， 以 乙酸乙酯 、 丙酮 为溶剂， 反应 48.0h， 生成 methyl 4-<(6-amino-2,3-dihydrobenz-1,4-oxazin-4-yl)methyl>-3-methoxybenzoate
  参考文献：
  名称：

  Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides

  摘要：

  The dissociation constants (KB) at the LTD4 receptor on guinea pig trachea of a series of monocyclic and bicyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides have been measured. The KB was found to be remarkably tolerant of changes in the electronic constitution and lipophilicity of the bicyclic ring system (template). Thus, N-[4[[6-[[(cyclopentyloxy)carbonyl]amino]benzimidazol-1- yl]methyl]-3-methoxybenzoyl]benzenesulfonamide (11a) and N-[4-[[5-[[(cyclopentyloxy)carbonyl]amino]benzo[b]thien-3- yl]methyl]-3-methoxybenzoyl]benzene-sulfonamide (25a) had closely similar affinities (pKB, 9.20 and 9.31, respectively; LTE4 as agonist). It has been shown that the hetero-ring of the template need not be aromatic in order to achieve high affinity, since indoline 31 and 2,3-dihydrobenz-1,4-oxazines 37a-c had pKBs greater than 9. Further, it has been shown that an o-aminophenone (see 42 and Figure 3) can function as a template; the template in 42 [see iii] is bicyclic by virtue of the presence of an intramolecular hydrogen bond. In contrast, when the template is a phenyl ring (48), receptor affinity is markedly reduced. These findings support the notion that central bicyclic ring system in this family of peptidoleukotriene antagonists is a molecular feature which helps to preorganize the acylamino and acidic chains and thereby facilitate the molecular recognition event.

  DOI：

  10.1021/jm00171a043

文献信息

• Heterocyclic amide derivatives and pharmaceutical use
  申请人：ICI Americas Inc.

  公开号：US04859692A1

  公开（公告）日：1989-08-22

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及某些苯并杂环基丙酸（及相关四唑和酰磺酰胺）的药用酰胺衍生物 I 及其盐，其中 R1、R2、L、X、Y、Z、A1、Q、A2 和 M 的含义如说明书中所述。本发明还包括含有 I 式化合物或其盐的药物组合物，制造所述化合物的过程以及用于该过程的中间体。
• Heterocyclic amide derivatives and use
  申请人：ICI Americas Inc.

  公开号：US05030643A1

  公开（公告）日：1991-07-09

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及某些苯并杂环烷基脂肪酸（及相关的四唑和酰基磺酰胺）的新型药用酰胺衍生物（式I）及其盐，其中基团R.sup.1、R.sup.2、L、X、Y、Z、A.sup.1、Q、A.sup.2和M的含义在规范中列出。本发明还包括包含式I化合物或其盐的制药组合物，以及用于后续过程的中间体的制造工艺。 ##STR1##
• Heterocyclic amide derivatives and pharmaceutical use thereof
  申请人：Zeneca Inc.

  公开号：US05338734A1

  公开（公告）日：1994-08-16

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及一种新型的药用酰胺衍生物，其为某些苯并杂环烷基脂肪酸（及相关的四唑和酰基磺酰胺）的衍生物，其化学式为I并包括其盐，其中基团R.sup.1，R.sup.2，L，X，Y，Z，A.sup.1，Q，A.sup.2和M的含义在说明书中给出。本发明还包括制备该化合物的方法，以及用于后续过程的中间体，以及包含化合物I或其盐的制药组合物。
• Method for treating vasospastic cardiovascular diseases heterocyclic
  申请人：Zeneca Inc.

  公开号：US05583152A1

  公开（公告）日：1996-12-10

  The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R.sup.1, R.sup.2, L, X, Y, Z, A.sup.1, Q, A.sup.2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. ##STR1##

  本发明涉及一种新型、具有药学意义的苯并杂环基烷酸（及相关四唑和酰基磺酰胺）的酰胺衍生物I及其盐，其中基团R.sup.1、R.sup.2、L、X、Y、Z、A.sup.1、Q、A.sup.2和M的含义如规范中所述。本发明还包括将公式I化合物或其盐纳入制药组合物中，制备该化合物的过程以及用于后续过程的中间体。 ##STR1##
• Heterocyclic amide derivatives
  申请人：ICI AMERICAS INC.

  公开号：EP0199543B1

  公开（公告）日：1991-12-04